Probiotic metabolites as epigenetic targets in the prevention of colon cancer

Nutrition Reviews

Volumn 71, Issue 1, 2013, Pages 23-34

  Kumar, Manoj ^a   Nagpal, Ravinder ^b   Verma, Vinod ^c   Kumar, Ashok ^d   Kaur, Navrinder ^e   Hemalatha, Rajkumar ^a   Gautam, Sanjeev K ^f   Singh, Birbal ^g  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b Department of Biotechnology   (India)

^c DEPARTMENT OF CARDIOLOGY   (Singapore)

^d Department of Botany   (India)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f KURUKSHETRA UNIVERSITY   (India)

^g INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

Colon cancer; Epigenetic alterations; Probiotic metabolites

Indexed keywords

APIGENIN; BUTYRIC ACID; CAPSAICIN; CASPASE 3; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOKINE; ELLAGITANNIN; HISTONE DEACETYLASE INHIBITOR; I KAPPA B ALPHA; INTERLEUKIN 10; JANUS KINASE 2; LYCOPENE; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; SILIBININ; SILYMARIN; SOMATOMEDIN C; STAT4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BUTYRIVIBRIO FIBRISOLVENS; CANCER PREVENTION; CANCER SCREENING; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; CYTOKINE PRODUCTION; ENZYME DEGRADATION; EPIGENETICS; GARLIC; HUMAN; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LIVER METABOLISM; METASTASIS; NONHUMAN; PROPIONIBACTERIUM FREUDENREICHII; PROTEIN EXPRESSION; SILYBUM MARIANUM;

CHEMOPREVENTION; COLONIC NEOPLASMS; DIETARY SUPPLEMENTS; EPIGENESIS, GENETIC; HUMANS; PROBIOTICS; SIGNAL TRANSDUCTION;

EID: 84871859202     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2012.00542.x     Document Type: Article

References (164)

1. Licciardi PV, Wong SS, Tang ML, etal. Epigenome targeting by probiotic metabolites. Gut Pathog. 2010;2:24.
2. Singh B, Gautam SK, Verma V, etal. Metagenomics in animal gastrointestinal tract: potential biotechnological applications. Anaerobe. 2008;14:138-144.
3. Singh B, Bhat TK, Singh B. Potential therapeutic applications of some antinutritional plant secondary metabolites. J Agric Food Chem. 2003;51:5579-5597.
4. Maslowski KM, Vieira AT, Ng A, etal. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-1286.
5. Oelschlaeger TA. Mechanisms of probiotic actions: a review. Int J Med Microbiol. 2010;300:57-62.
6. Felis GE, Dellaglio F. Taxonomy of lactobacilli and bifidobacteria. Curr Issues Intest Microbiol. 2007;8:44-61.
7. Nagpal R, Yadav H, Puniya AK, etal. Potential of probiotics and prebiotics for synbiotic functional dairy foods. Int J Probiotics Prebiotics. 2007;2:75-84.
8. Kleerebezem M, Vaughan EE. Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. Ann Rev Microbiol. 2009;63:269-290.
9. Weiss G, Christensen HR, Zeuthen LH, etal. Lactobacilli and bifidobacteria induce differential interferon-β profiles in dendritic cells. Cytokine. 2011;56:520-530.
10. Walter H, Claus R. Expression of the monocarboxylate transporter-1 (MCT1) in cells of the porcine intestine. Cell Biol Intern. 2008;32:638-645.
11. Perić-Concha N, Long PF. Mining the microbial metabolome: a new frontier for natural product lead discovery. Drug Disc Today. 2003;8:1078-1084.
12. Arora T, Sharma RK. Fermentation potential of the gut microbiome: implications for energy homeostasis and weight management. Nutr Rev. 2010;69:99-106.
13. Turnbaugh PJ, Ley RE, Hamady M, etal. The human microbiome project. Nature. 2007;449:804-810.
14. Kumar M, Mohania D, Kumar A, etal. Metabolomics: an emerging tool for nutrition and health aspect. Curr Topics Nutraceut Res. 2009;7:97-104.
15. O'Shea EF, Cotter PD, Stanton C, etal. Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: bacteriocins and conjugated linoleic acid. Int J Food Microbiol. 2012;152:189-205.
16. Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull. 2002;64:1-25.
17. Stewart BE, Kleinhues P. World Cancer Report. Lyon, France: IARC Press; 2003.
18. Jemal A, Siegel R, Ward E, etal. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
19. Kahi CJ, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology. 2008;135:380-399.
20. Jass JR. Limitations of the adenoma-carcinoma sequence in colorectum. Clin Cancer Res. 2004;10:5969-5970.
21. Nambiar PR, Gupta RR, Misra V. An "Omics" based survey of human colon cancer. Mutat Res. 2010;693:3-18.
22. Willett WC. Diet, nutrition, and avoidable cancer. Environ Health Persp. 1995;103:165-170.
23. Singh B, Mukesh M, Sodhi M, etal. Nutrigenomics, metabolomics and metabonomics: emerging faces of molecular genomics and nutrition. In: Knapp JS, Cabrera WL, eds. Metabolomics: Metabolites, Metabonomics and Analytical Technologies. Hauppauge, NY: Nova Science Publishers, Inc; 2011. pp 201-213.
24. O'Keefe SJ. Nutrition and colonic health: the critical role of the microbiota. Curr Opin Gastroenterol. 2008;24:51-58.
25. Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73:S451-S455.
26. de Moreno de LeBlanc A, Matar C, Perdigón G. The application of probiotics in cancer. Br J Nutr. 2007;98:S105-S110.
27. Le Leu RK, Brown IL, Hu Y, etal. A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. J Nutr. 2005;135:996-1001.
28. Ohkawara S, Furuya H, Nagashima K, etal. Oral administration of Butyrivibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. J Nutr. 2005;135:2878-2883.
29. Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer? Cancer Biol Ther. 2006;5:1265-1269.
30. Balamurugan R, Aarthi CM, Chittaranjan SP, etal. Molecular detection of the ruminal bacterium, Butyrivibrio fibrisolvens, in feces from rural residents of southern India. Microbial Ecol Health Dis. 2009;21:38-43.
31. Kumar M, Kumar A, Nagpal R, etal. Cancer-preventing attributes of probiotics: an update. Int J Food Sci Nutr. 2010;61:473-496.
32. Kumar M, Verma V, Nagpal R, etal. Anticarcinogenic effect of probiotic fermented milk and chlorophyllin on aflatoxin-B1-induced liver carcinogenesis in rats. Br J Nutr. 2012;107:1006-1016.
33. Tappenden KA, Deutsch AS. The physiological relevance of the intestinal microbiota: contributions to human health. J Am Coll Nutr. 2007;26:S679-S683.
34. Ishikawa I, Akedo I, Otani T, etal. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer. 2005;116:762-767.
35. Otles S, Cagindi O, Akcicek E. Probiotics and health. Asian Pac J Cancer Prev. 2003;4:369-372.
36. O'Sullivan GC, Kelly P, O'Halloran S, etal. Probiotics: an emerging therapy. Curr Pharm Des. 2005;11:3-10.
37. Davis CD, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem. 2009;20:743-752.
38. Wolvers D, Antoine JM, Myllyluoma E, etal. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr. 2010;140:S698-S712.
39. Osawa R, Fujisawa T, Pukall R. Lactobacillus apodami sp. nov., a tannase-producing species from wild mouse faeces. Int J Syst Evol Microbiol. 2006;56:1693-1696.
40. Rodriguez H, de las Rivas B, Gomez-Cordoves C, etal. Characterization of tannase activity in cell-free extracts of Lactobacillus plantarum CECT 748T. Int J Food Microbiol. 2008;121:92-98.
41. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38:S104-S106.
42. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut. 2003;52:988-997.
43. Snelling AM. Effects of probiotics on the gastrointestinal tract. Curr Opin Infect Dis. 2005;18:420-426.
44. Kaput J, Perlina A, Hatipoglu B, etal. Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. Pharmacogenomics. 2007;8:369-390.
45. Inselman AL, Hansen DK, Lee HY, etal. Assessment of research models for testing gene-environment interactions. Eur J Pharmacol. 2011;668(Suppl 1):S108-S116.
46. Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003;62:67-72.
47. Avivi-Green C, Polak-Charcon S, Madar Z, etal. Apoptosis cascade proteins are regulated in vivo by high intracolonic butyrate concentration: correlation with colon cancer inhibition. Oncol Res. 2000;12:83-95.
48. Hofmanová J, Vaculová A, Lojek A, etal. Interaction of polyunsaturated fatty acids and sodium butyrate during apoptosis in HT-29 human colon adenocarcinoma cells. Eur J Nutr. 2005;44:40-51.
49. Hofmanová J, Vaculová A, Koubková Z, etal. Human fetal colon cells and colon cancer cells respond differently to butyrate and PUFAs. Mol Nutr Food Res. 2009;53:S102-S113.
50. Chapkin RS, Seo J, McMurray DN, etal. Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chem Phys Lipids. 2008;153:14-23.
51. Cummings JH, Pomare EW, Branch WJ, etal. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28:1221-1227.
52. Hoverstad T. Studies of short-chain fatty acid absorption in man. Scand J Gastroenterol. 1986;21:257-260.
53. Velazquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications. Adv Exp Med Biol. 1997;427:123-134.
54. Candela M, Maccaferri S, Turroni S, etal. Functional intestinal microbiome, new frontiers in prebiotic design. Int J Food Microbiol. 2010;140:93-101.
55. Cummings JH, Rombeau JL, Sakata T. Physiological and Clinical Aspects of Short-Chain Fatty Acids. Cambridge, UK: Cambridge University Press; 1995.
56. Andoh A, Tsujikawa T, Fujiyama Y. Role of dietary fiber and short-chain fatty acids in the colon. Curr Pharm Des. 2003;9:347-358.
57. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res. 2005;49:601-608.
58. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401-1412.
59. Diakos C, Prieschl EE, Saemann M, etal. Novel mode of interference with nuclear factor of activated T-cells regulation in T-cells by the bacterial metabolite n-butyrate. J Biol Chem. 2002;277:24243-24251.
60. Luhrs H, Gerke T, Muller JG, etal. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002;37:458-466.
61. Djouzi Z, Andrieux C, Degivry MC, etal. The association of yogurt starters with Lactobacillus casei DN 114.001 in fermented milk alters the composition and metabolism of intestinal microflora in germ-free rats and in human flora-associated rats. J Nutr. 1997;127:2260-2266.
62. Delzenne N, Cherbut C, Neyrinck A. Prebiotics: actual and potential effects in inflammatory and malignant colonic diseases. Curr Opin Clin Nutr Metab Care. 2003;6:581-586.
63. Kiela PR, Kuscuoglu N, Midura AJ, etal. Molecular mechanism of rat NHE3 gene promoter regulation by sodium butyrate. Am J Physiol Cell Physiol. 2007;293:C64-C74.
64. Sauer J, Richter KK, Pool-Zobel BL. Physiological concentrations of butyrate favorably modulate genes of oxidative and metabolic stress in primary human colon cells. J Nutr Biochem. 2007;18:736-745.
65. Walter J. Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research. Appl Environ Microbiol. 2008;74:4985-4996.
66. Marks PA, Richon VM, Miller T, etal. Histone deacetylase inhibitors. Adv Cancer Res. 2004;91:137-168.
67. Acharya MR, Sparreboom A, Venitz J, etal. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol. 2005;68:917-932.
68. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003;133(Suppl 1):S2485-S2493.
69. Waldecker M, Kautenburger T, Daumann H, etal. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem. 2008;19:587-593.
70. Singh N, Thangaraju M, Prasad PD, etal. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J Biol Chem. 2010;285:27601-27608.
71. Saikali J, Picard C, Freitas M, etal. Fermented milks, probiotic cultures, and colon cancer. Nutr Cancer. 2004;49:14-24.
72. De Preter V, Hamer HM, Windey K, etal. The impact of pre- and/or probiotics on human colonic metabolism: does it affect human health? Mol Nutr Food Res. 2011;55:46-57.
73. Van Immerseel F, Ducatelle R, De Vos M, etal. Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol. 2010;59:141-143.
74. Sokol H, Seksik P, Furet JP, etal. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15:1183-1189.
75. Sokol H, Pigneur B, Watterlot L, etal. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105:16731-16736.
76. Lan A, Lagadic-Gossmann D, Lemaire C, etal. Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. Apoptosis. 2007;12:573-591.
77. Hinnebusch BF, Meng S, Wu JT, etal. The effects of short chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr. 2002;132:1012-1017.
78. Hodin RA, Meng S, Archer S, etal. Cellular growth state differentially regulates enterocyte gene expression in butyrate- treated HT- 29 cells. Cell Growth Differ. 1996;7:647-653.
79. Chirakkal H, Leech SH, Brookes KE, etal. Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding. Oncogene. 2006;25:7192-7200.
80. Comalada M, Bailón E, de Haro O, etal. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol 2006;132:487-497.
81. Alrawi SJ, Schiff M, Carroll RE, etal. Aberrant crypt foci. Anticancer Res. 2006;26:107-119.
82. Maier S, Daroqui MC, Scherer S, etal. Butyrate and vitamin D3 induce transcriptional attenuation at the cyclin D1 locus in colonic carcinoma cells. J Cell Physiol. 2009;218:638-642.
83. Daroqui MC, Augenlicht LH. Transcriptional attenuation in colon carcinoma cells in response to butyrate. Cancer Prev Res (Phila). 2010;3:1292-1302.
84. Scharlau D, Borowicki A, Habermann N, etal. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fiber. Mutat Res. 2009;682:39-53.
85. Chen YX, Fang JY, Lu J, etal. Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines [in Chinese]. Zhonghua Yi Xue Za Zhi. 2004;84:312-317.
86. Yu DC, Waby JS, Chirakkal H, etal. Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Mol Cancer. 2010;9:276.
87. Ruemmele FM, Dionne S, Qureshi I, etal. Butyrate mediates Caco-2 cell apoptosis via up-regulation of pro-apoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP). Cell Death Differ. 1999;6:729-735.
88. Ruemmele FM, Schwartz S, Seidman EG, etal. Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut. 2003;52:94-100.
89. Thangaraju M, Cresci GA, Liu K, etal. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009;69:2826-2832.
90. Soga T, Kamohara M, Takasaki J, etal. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003;303:364-369.
91. Wise A, Foord SM, Fraser NJ, etal. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278:9869-9874.
92. Astbury SM, Corfe BM. Uptake and metabolism of short chain fatty acid butyrate, a critical review of the literature. Curr Drug Metab. 2012;13:815-821.
93. Pool-Zobel B, Veeriah S, Böhmer FD. Modulation of xenobiotic metabolizing enzymes by anticarcinogens focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mut Res. 2005;591:74-92.
94. Howe GR, Benito E, Castelleto R, etal. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst. 1992;84:1887-1896.
95. Burkitt DP. Epidemiology of cancer of the colon and rectum. Dis Colon Rectum. 1993;36:1071-1082.
96. Cassidy A, Bingham SA, Cummings JH. Starch intake and colorectal cancer risk: an international comparison. Br J Cancer. 1994;69:937-942.
97. Kim YI. AGA technical review: impact of dietary fiber on colon cancer occurrence. Gastroenterology. 2000;118:1235-1257.
98. Bordonaro M, Lazarova DL, Sartorelli AC. Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk? Cell Cycle. 2008;7:1178-1183.
99. Burns AJ, Rowland IR. Anti-carcinogenicity of probiotics and prebiotics. Curr Issues Intest Microbiol. 2000;1:13-24.
100. Nagpal R, Kaur A. Synbiotic effect of various prebiotics on in-vitro activities of probiotic lactobacilli. Ecol Food Nutr. 2011;50:63-68.
101. Migliore L, Migheli F, Spisni R, etal. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011;2011:792362.doi:10.1155/2011/792362.
102. Yan F, Polk DB. Probiotics and immune health. Curr Opin Gastroenterol. 2011;27:496-501.
103. Amdekar S, Dwivedi D, Roy P, etal. Probiotics: multifarious oral vaccine against infectious traumas. FEMS Immunol Med Microbiol. 2010;58:299-306.
104. Kukkonen K, Savilahti E, Haahtela T, etal. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2007;119:192-198.
105. Wickens K, Black PN, Stanley TV, etal. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2008;122:788-794.
106. Kalliomaki M, Salminen S, Arvilommi H, etal. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet. 2001;357:1076-1079.
107. Kopp MV, Hennemuth I, Heinzmann A, etal. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics. 2008;121:e850-e856.
108. Lammers KM, Helwig U, Swennen E, etal. Effect of probiotic strains on interleukin-8 production by HT29/19A cells. Am J Gastroenterol. 2002;97:1182-1186.
109. Neish AS. Bacterial inhibition of eukaryotic pro-inflammatory pathways. Immunol Res. 2004;29:175-186.
110. Ruiz PA, Hoffmann M, Szcesny S, etal. Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats. Immunology. 2005;115:441-450.
111. Hart AL, Lammers K, Brigidi P, etal. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602-1609.
112. Pessi T, Sutas Y, Hurme M, etal. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy. 2000;30:1804-1808.
113. Rautava S. Potential uses of probiotics in the neonate. Semin Fetal Neonatal Med. 2007;12:45-53.
114. Pohjavuori E, Viljanen M, Korpela R, etal. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol. 2004;114:131-136.
115. Isolauri E, Joensuu J, Suomalainen H, etal. Improved immunogenicity of oral D × RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 1995;13:310-312.
116. Mullie C, Yazourh A, Thibault H, etal. Increased poliovirus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatr Res. 2004;56:791-795.
117. von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin Diagn Lab Immunol. 2001;8:695-701.
118. van Baarlen P, Troost F, van der Meer C, etal. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Nat Acad Sci USA. 2011;108(Suppl 1):S4562-S4569.
119. Cresci GA, Thangaraju M, Mellinger JD, etal. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J Gastrointest Surg. 2010;14:449-461.
120. Waldecker M, Kautenburger T, Daumann H, etal. Histone-deacetylase inhibition and butyrate formation: fecal slurry incubations with apple pectin and apple juice extracts. Nutrition. 2008;24:366-374.
121. Bordin M, D'Atri F, Guillemot L, etal. Histone deacetylase inhibitors upregulate the expression of tight junction proteins. Mol Cancer Res. 2004;2:692-701.
122. Peng L, Li ZR, Green RS, etal. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139:1619-1625.
123. King-Batoon A, Leszczynska J, Klein C. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ Mol Mutagen. 2008;49:36-45.
124. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr. 2004;134:479-482.
125. Singh BN, Zhang G, Hwa YL, etal. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther. 2010;10:935-954.
126. Putala H, Makivuokko H, Tiihonen K, etal. Stimulated colon fiber metabolome regulates genes involved in cell cycle, apoptosis, and energy metabolism in human colon cancer cells. Mol Cell Biochem. 2011;357:235-245.
127. Kang J, Chen J, Shi Y, etal. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem Pharmacol. 2005;15:1205-1213.
128. Marcu MG, Jung YJ, Lee S, etal. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem. 2006;2:169-174.
129. Jiang MC, Yang-Yen HF, Yen JJ, etal. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer. 1996;26:111-120.
130. Lin C, Lin J. Curcumin: a potential chemopreventive agent through suppressing NF-κB signaling. J Cancer Molecules. 2008;4:11-16.
131. Mimeault M, Batra SK. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med. 2011;6:31.
132. Fang M, Chen D, Yang C. Dietary polyphenols may affect DNA methylation. J Nutr. 2007;137:S223-S228.
133. Lee SH, Richardson RL, Dashwood RH, etal. Capsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells. J Nutr Biochem. 2012;23:646-655.
134. Dou D, Ahmad A, Yang H, etal. Tumor cell growth inhibition is correlated with levels of capsaicin present in hot peppers. Nutr Cancer. 2011;63:272-281.
135. Demestre M, Messerli SM, Celli N, etal. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Phytother Res. 2009;23:226-230.
136. Wang T, Chen L, Wu W, etal. Potential cytoprotection: antioxidant defence by caffeic acid phenethyl ester against free radical-induced damage of lipids, DNA, and proteins. Can J Physiol Pharmacol. 2008;86:279-287.
137. Papoutsis AJ, Lamore SD, Wondrak GT, etal. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J Nutr. 2010;140:1607-1614.
138. Stefanska B, Rudnicka K, Bednarek A, etal. Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells. Eur J Pharmacol. 2010;638:47-53.
139. Kaeberlein M, McDonagh T, Heltweg B, etal. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem. 2005;280:17038-17045.
140. Boily G, He XH, Pearce B, etal. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene. 2009;28:2882-2893.
141. Majid S, Kikuno N, Nelles J, etal. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res. 2008;68:2736-2744.
142. Adlercreutz H, Bannwart C, Wahala K, etal. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol. 1993;44:147-153.
143. Akiyama T, Ishida J, Nakagawa S, etal. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592-5595.
144. Fotsis T, Pepper M, Adlercreutz H, etal. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr. 1995;125:S790-S797.
145. Kikuno N, Shiina H, Urakami S, etal. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer. 2008;123:552-560.
146. Li Y, Liu L, Andrews LG, etal. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer. 2009;125:286-296.
147. Balabhadrapathruni S, Thomas TJ, Yurkow EJ, etal. Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDAMB-468 human breast cancer cells. Oncol Rep. 2000;7:3-12.
148. Fang M, Wang Y, Ai N, etal. Tea polyphenol (-)-epigallocatechin-3- gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63:7563-7570.
149. Kato K, Long NK, Makita H, etal. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br J Cancer. 2008;99:647-654.
150. Pandey M, Shukla S, Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer. 2010;126:2520-2533.
151. Lee W, Shim J, Zhu B. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol. 2005;68:1018-1030.
152. Choi KC, Jung MG, Lee YH, etal. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 2009;69:583-592.
153. Chung S, Yao H, Caito S, etal. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys. 2010;501:79-90.
154. Meeran S, Patel S, Tollefsbol T. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS ONE. 2010;5:e11457.
155. Traka M, Gasper A, Smith J, etal. Transcriptome analysis of human colon Caco-2 cells exposed to sulforaphane. J Nutr. 2005;135:1865-1872.
156. Myzak MC, Tong P, Dashwood WM, etal. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med. 2007;232:227-234.
157. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol. 2007;17:363-369.
158. Ho E, Clarke JD, Dashwood RH. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr. 2009;139:2393-2396.
159. Myzak MC, Karplus PA, Chung FL, etal. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 2004;64:5767-5774.
160. Li LH, Wu LJ, Tashiro SI, etal. Activation of the SIRT1 pathway and modulation of the cell cycle were involved in silymarin's protection against UV-induced A375-S2 cell apoptosis. J Asian Nat Prod Res. 2007;9:245-252.
161. Hogan FS, Krishnegowda NK, Mikhailova M, etal. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 2007;143:58-65.
162. Velmurugan B, Singh RP, Tyagi A, etal. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila). 2008;1:376-384.
163. Rajamanickam S, Kaur M, Velmurugan B, etal. Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway. Pharm Res. 2009;26:2558-2567.
164. Rajamanickam S, Velmurugan B, Kaur M, etal. Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res. 2010;70:2368-2378.